We will not be receiving specimens on Monday, May 30 in observance of Memorial Day. Please take this into consideration when shipping cell cultures and time-sensitive specimens. Our regular shipping and receiving instructions apply to all other days over this holiday weekend.
We recently released an option for our pre-defined panels to be run on a PGnome® (genome) sequencing backbone. But you may be wondering … what’s a backbone?
The last thing many people want to think about is their own mortality, which often leaves their families to deal with funeral planning, expenses and, sometimes, unresolved medical decisions. They turn to you as a resource in their time of grief. As a funeral director, your interaction with families during a time of loss is their last opportunity to preserve a loved one’s DNA.
Inherited kidney diseases have an overall prevalence of ~6-8 in 10,000 births in the United States and Europe, and accounts for up to 37% of adults with renal diseases (Cocchi et al. 2020. PubMed ID: 32646915; Connaughton et al. 2019. PubMed ID: 30773290; Lata et al. 2018. PubMed ID: 29204651). Obtaining an early diagnosis for kidney disease is important for establishing optimal maintenance and treatment plans for patients and their families, which is why genetic testing has been increasingly integrated into clinical practice.
Early detection and diagnosis of Congenital Heart Defects (CHDs) is essential to guide patient care. Survival and medical care for children with CHDs are improving. Among states with mandatory CHD screening via pulse oximetry, a 33.4% reduction of early infant deaths due to CHD was observed (Abouk et al., 2017). Initial diagnosis is only the beginning. Genetic testing for CHD also plays an important role in improving outcomes.
